Fulgent Genetics, Inc. reiterated earnings guidance for the year 2024. For the full year 2024, Fulgent continues to expect Core Revenue of approximately $280 million and GAAP loss of approximately $2.25 per share.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.39 USD | +1.18% | -3.26% | -26.01% |
May. 03 | Transcript : Fulgent Genetics, Inc., Q1 2024 Earnings Call, May 03, 2024 | |
May. 03 | Earnings Flash (FLGT) FULGENT GENETICS Posts Q1 Revenue $64.5M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-26.01% | 640M | |
-23.69% | 7.86B | |
+68.36% | 4.32B | |
+2.12% | 2.63B | |
-7.18% | 2.5B | |
-42.85% | 2.33B | |
-11.99% | 1.82B | |
-20.68% | 1.51B | |
+17.83% | 1.22B | |
-42.71% | 1.14B |
- Stock Market
- Equities
- FLGT Stock
- News Fulgent Genetics, Inc.
- Fulgent Genetics, Inc. Reiterates Earnings Guidance for the Year 2024